-+ 0.00%
-+ 0.00%
-+ 0.00%

AIM ImmunoTech Significantly Expands Ampligen® Global Patent Estate with Long COVID Protection Across Europe and the United Kingdom Through 2041

Barchart·09/02/2026 07:43:00
Listen to the news

Patent protections establish long-duration intellectual property coverage for Ampligen across major European markets and the United Kingdom

Latest milestone further strengthens AIM’s expanding global Ampligen patent estate across multiple therapeutic opportunities

Read more at globenewswire.com

This article contains syndicated content. We have not reviewed, approved, or endorsed the content, and may receive compensation for placement of the content on this site. For more information please view the Barchart Disclosure Policy here.